Bedside Snapshot
  • Core dose: Seizures: 0.15–0.2 mg/kg IV (max 10 mg) at ≤5 mg/min, may repeat once; agitation: 2–10 mg IV titrated to effect; alcohol withdrawal: 10–20 mg IV/PO every 5–15 min until calm; rectal 0.5 mg/kg (max 20 mg) if no IV
  • Onset/duration: IV onset 1–3 min, rectal 5–10 min; anticonvulsant effect ~15–30 min after single IV bolus due to redistribution; elimination half-life 20–50 h (active metabolites 30–100+ h)
  • Key danger: Respiratory depression/apnea (especially with opioids or alcohol); hypotension; accumulation with repeated dosing (long-acting metabolites); paradoxical agitation (rare); avoid IM (erratic absorption)
  • Special: Benzodiazepine (GABA_A positive allosteric modulator); high lipophilicity → rapid CNS penetration but redistributes quickly; can use rectal route if no IV; flumazenil is reversal agent (use cautiously in seizure patients); propylene glycol vehicle
Brand & Generic Names
  • Generic Name: diazepam (oral/IV/rectal)
  • Brand Names: Valium (PO/IV), Diastat/Diastat AcuDial (rectal gel)
Medication Class

Benzodiazepine; anticonvulsant, anxiolytic, sedative-hypnotic, muscle relaxant

Pharmacology

Mechanism of Action:

  • Positive allosteric modulator of GABA_A receptors at the benzodiazepine site
  • Rapid CNS penetration due to high lipophilicity
  • Anticonvulsant effect is fast but redistributes from brain to peripheral tissues within ~15–30 min after IV dose

Pharmacokinetics (clinically relevant):

  • Onset: IV 1–3 min; PR ~5–10 min; IM is erratic/slow—avoid for emergencies
  • Duration (anticonvulsant): ~15–30 min after single IV bolus due to redistribution (despite long elimination half-life)
  • Half-life: diazepam ~20–50 h; active metabolite desmethyldiazepam (nordiazepam) 30–100+ h → accumulation with repeated dosing, especially elderly/hepatic impairment
  • Metabolism: hepatic (CYP2C19, CYP3A4) to desmethyldiazepam, temazepam, oxazepam
  • Protein binding: highly protein bound (~98–99%)
  • Elimination: hepatic/biliary; renal excretion of metabolites. Not dialyzable in overdose to any meaningful degree
Indications
  • Status epilepticus/acute repetitive seizures
  • Sedation and agitation control in hyperadrenergic states (e.g., stimulant toxicity), serotonin syndrome (adjunct), and tetanus
  • Alcohol withdrawal/DTs (symptom-triggered or loading strategies)
  • Muscle spasm (e.g., severe back spasm) and spasticity (adjunct)
  • Chemical agent/nerve agent seizure control (CANA auto-injector; military/CBRN protocols)
Conditions Treated
  • Status epilepticus
  • Acute repetitive seizures
  • Stimulant toxicity (agitation control)
  • Serotonin syndrome
  • Alcohol withdrawal syndrome / Delirium tremens
  • Severe muscle spasm and spasticity
  • Tetanus
  • Nerve agent exposure (seizure control)
Dosing & Administration

Available Forms:

  • Injection: 5 mg/mL (2 mL = 10 mg; 10 mL = 50 mg)
  • Rectal gel (Diastat): weight-based prefilled doses (2.5–20 mg)
  • Oral tablets: 2 mg, 5 mg, 10 mg

Adult Dosing:

Indication Dose Notes
Status epilepticus/active seizure 0.15–0.2 mg/kg IV (max 10 mg) at ≤5 mg/min May repeat once after 5–10 min. If IV unavailable, PR 0.5 mg/kg (max 20 mg)
Acute agitation/hyperadrenergic toxicity 2–10 mg IV Repeat titrated to effect and BP/respiratory status
Alcohol withdrawal 10–20 mg IV/PO every 5–15 min until calm but arousable Then scheduled/PRN per CIWA or ICU protocol; high cumulative doses may be required
Muscle spasm 2–10 mg PO/IV every 6–8 h as needed Use lowest effective dose

Pediatric Dosing:

  • Seizure: IV/IO 0.2 mg/kg (max 10 mg), may repeat once; PR 0.5 mg/kg (max 20 mg)
  • Rectal gel (Diastat) rescue: 0.2–0.5 mg/kg with rounding to prefilled strengths; one repeat dose after 4–12 h per labeling/protocol

Administration:

  • Administer undiluted IV push into a large vein; avoid mixing with other drugs/fluids
  • Injection is nonaqueous and incompatible with many solutions—administer via slow IV push into a running line
  • Do not mix with other medications
Contraindications

Contraindications:

  • Acute narrow-angle glaucoma
  • Severe respiratory insufficiency without ventilatory support
  • Hypersensitivity to benzodiazepines

Boxed Warnings:

  • Concomitant use with opioids may cause profound sedation, respiratory depression, coma, and death
  • Risk of abuse, misuse, and addiction
  • Physical dependence and withdrawal reactions

Precautions:

  • Use caution in hepatic impairment (risk of oversedation/encephalopathy)
  • Elderly (falls, delirium)
  • Sleep apnea
  • Myasthenia gravis
  • Substance use disorders
  • Pregnancy (neonatal CNS/respiratory depression if used near delivery)
  • Avoid routine IM route (erratic absorption, tissue irritation)
Opioid Combination: Concomitant use with opioids increases risk of profound sedation, respiratory depression, coma, and death.
Adverse Effects

Dose-related CNS Depression:

  • Somnolence
  • Ataxia
  • Confusion
  • Anterograde amnesia
  • Paradoxical agitation (rare)

Cardiorespiratory:

  • Respiratory depression, especially with other CNS depressants or rapid IV push
  • Hypotension

Local:

  • Pain, thrombophlebitis
  • Propylene glycol–containing injection can cause hypotension/metabolic acidosis with high cumulative dosing
Drug Interactions
  • Opioids, alcohol, antihistamines, antipsychotics, other sedatives: Additive CNS/respiratory depression
  • CYP3A4/CYP2C19 inhibitors (fluconazole, fluoxetine, omeprazole, cimetidine, clarithromycin): May increase diazepam levels
  • CYP inducers (rifampin, carbamazepine): May decrease effect
  • Clozapine: Avoid during acute titration (respiratory/circulatory collapse reported); monitor closely if necessary
Clinical Pearls
Status Epilepticus: Follow diazepam with a longer-acting antiepileptic (e.g., levetiracetam, fosphenytoin, valproate) because anticonvulsant effect of a single bolus is short (redistribution).
Route Selection: Prefer IV/IO or rectal over IM for emergencies. If only IM route is available, midazolam is preferred.
Alcohol Withdrawal: Titrate using symptom-triggered protocols when possible; diazepam's long half-life smooths rebound between doses.
Flumazenil Caution: Avoid flumazenil in undifferentiated overdose or chronic benzodiazepine users—can precipitate refractory seizures; reserve for select iatrogenic cases with airway secured.
Stimulant Toxicity/Serotonin Syndrome: Benzodiazepines are first-line to control agitation and autonomic hyperactivity; treat hyperthermia with external cooling (avoid antipsychotics in severe stimulant toxicity).
Administration Compatibility: Injection is nonaqueous and incompatible with many solutions—administer undiluted via slow IV push into a running line; do not mix with other medications.
References
  • 1. Papadopoulos, J. (2008). Pocket guide to critical care pharmacotherapy. Humana Press.
  • 2. Medscape. (n.d.). Diazepam (Valium, Diastat) – drug monograph & dosing. Retrieved 2025-11-12, from https://reference.medscape.com
  • 3. Medscape. (n.d.). Status epilepticus: Treatment & management. Retrieved 2025-11-12, from https://emedicine.medscape.com
  • 4. Medscape. (n.d.). Alcohol withdrawal syndrome: Treatment. Retrieved 2025-11-12, from https://emedicine.medscape.com
  • 5. DrugBank Online. (n.d.). Diazepam (DB00829). Retrieved 2025-11-12, from https://go.drugbank.com/drugs/DB00829
Back to Medication Index
Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing and formatting this information. All content is reviewed for accuracy.